Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure.
Drugmaker Bristol-Myers Squibb Co. is suspending a midstage study of a potential hepatitis C treatment because of a serious patient safety issue.
Drugmaker Bristol-Myers Squibb Co. is cutting jobs again, this time eliminating about 3 percent of its positions in its latest effort to streamline operations.
